Literature DB >> 7478511

Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells.

T Tamura1, N Aoyama, H Saya, H Haga, S Futami, M Miyamoto, T Koh, T Ariyasu, M Tachi, M Kasuga.   

Abstract

To investigate the biological function of p53 in colon carcinoma cells, a wild-type p53 expression plasmid under the control of the human cytomegalovirus promoter was stably transfected into the human colon adenocarcinoma cell line WiDr, which carries a mutation of the p53 gene at codon 273. Exogenous wild-type p53 transcripts were detected at various expression levels in 8 of 117 G418-resistant clones. The growth rates of the wild-type p53+ clones in culture did not change significantly. The efficiency of colony formation in soft agar, however, was completely suppressed in two wild-type p53+ clones. This is the first to demonstrate the feasibility of stable transfection of the wild-type p53 gene under the control of non-inducible promoter in human colon cancer cells. The major alteration found was that wild-type p53+ cells which were incubated with anti-Fas IgM showed marked cytolysis with preferential over-expression of wild-type p53 accompanied by overexpression of a cyclin-dependent kinase inhibitor, WAF1, whereas the endogenous mutant p53 retained its expression level. The findings suggest that a Fas-initiated pathway is incidentally linked to a p53-dependent apoptotic pathway through the reconstituted wild-type p53 gene in WiDr cells. This model should help elucidating the additional role of the p53 tumor suppressor gene and the mechanism of apoptosis in colon carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7478511

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Thymineless death in colon carcinoma cells is mediated via fas signaling.

Authors:  J A Houghton; F G Harwood; D M Tillman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

2.  Gallium compound GaQ(3) -induced Ca(2+) signalling triggers p53-dependent and -independent apoptosis in cancer cells.

Authors:  Rajan Gogna; Esha Madan; Bernhard Keppler; Uttam Pati
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines.

Authors:  Manabu Taura; Ayaka Eguma; Mary Ann Suico; Tsuyoshi Shuto; Tomoaki Koga; Kensei Komatsu; Takefumi Komune; Takashi Sato; Hideyuki Saya; Jian-Dong Li; Hirofumi Kai
Journal:  Mol Cell Biol       Date:  2008-09-08       Impact factor: 4.272

Review 4.  The Fas counterattack: a molecular mechanism of tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

5.  Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model.

Authors:  C Blattmann; M Thiemann; A Stenzinger; A Christmann; E Roth; V Ehemann; J Debus; A E Kulozik; W Weichert; P E Huber; S Oertel; A Abdollahi
Journal:  Strahlenther Onkol       Date:  2013-06-27       Impact factor: 3.621

6.  Nuclear localization of the NS3 protein of hepatitis C virus and factors affecting the localization.

Authors:  S Muramatsu; S Ishido; T Fujita; M Itoh; H Hotta
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 7.  Shared pathways: death receptors and cytotoxic drugs in cancer therapy.

Authors:  I Peták; J A Houghton
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 8.  Studies of murine systemic autoimmunity.

Authors:  Philip L Cohen
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

9.  The transcription factor MEF/Elf4 is dually modulated by p53-MDM2 axis and MEF-MDM2 autoregulatory mechanism.

Authors:  Mary Ann Suico; Ryosuke Fukuda; Rui Miyakita; Kosuke Koyama; Manabu Taura; Tsuyoshi Shuto; Hirofumi Kai
Journal:  J Biol Chem       Date:  2014-07-31       Impact factor: 5.157

Review 10.  T cell-tumor cell: a fatal interaction?

Authors:  D B Chappell; N P Restifo
Journal:  Cancer Immunol Immunother       Date:  1998-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.